customer order manager salary cardinal healt

#Customer order manager salary cardinal healt full

Average diluted shares outstanding were 289 million, about 4 million shares fewer than the prior year. Our first quarter effective tax rate was approximately 24%. We continue to expect to repay the approximately $280 million of remaining June 2022 notes upon maturity. During the first quarter, we exercised a make-whole call provision to redeem $572 million of outstanding June 2022 debt maturities. Moving below the line interest and other decreased by $2 million, driven primarily by lower interest expense from continued debt reduction actions. Overall, first quarter operating earnings tracked in line with our expectations, down 15%. SG&A increased 1%, reflecting information technology investments and higher costs to support sales growth, partially offset by the Cordis divestiture and benefits from cost savings initiatives. As a reminder, the sale of Cordis was completed on August 2 and impacted the quarter's results by approximately two months. Total gross margin decreased 4% to $1.6 billion driven by the Cordis divestiture and the net impact of elevated supply chain costs in Medical. I will review our first quarter results and updated expectations for fiscal '22 before closing with some comments on capital deployment.īeginning with total company results first quarter revenue increased 13% to $44 billion, driven by sales growth from existing customers. Now, I'll turn it over to Jason to discuss our results. Looking ahead, we remain confident in our strategy. And with our improved balance sheet, commitment to our dividend and now an additional $3 billion share repurchase authorization, we're positioned to return capital to shareholders. We are prioritizing investment in our strategic growth areas and in innovative solutions to meet our customers' needs today and tomorrow. We have been on a journey to simplify our portfolio and strengthen our core businesses, so we are positioned for broad-based sustainable growth as noted in the long-term targets we're announcing today. We are taking action to mitigate these impacts across the enterprise and we are reaffirming our FY '22 EPS guidance of $5.60 to $5.90 per share. As a result, we are lowering our FY '22 outlook for Medical segment profit to adjust for these increased headwinds. While we believe the majority of these elevated supply chain costs are temporary, we do not expect them to return to normalized levels this fiscal year. Recently, these pressures have rapidly escalated and we are experiencing significantly elevated product costs due to international freight and commodities. Our Medical segment continues to be impacted by the disruptions in the global supply chain that we called out last quarter. We believe our Pharma business, inclusive of our strategic growth areas of Specialty, Nuclear and Outcomes, is well positioned for growth in FY '22 and beyond. In Pharma, we continue to see sequential volume improvement and are encouraged by the profit growth that we saw in the first quarter. As we continue to manage through the global pandemic, we're staying focused on the near-term priorities and long-term strategies to drive growth and momentum across our businesses. Our first quarter results were in line with our expectations. Thank you, Kevin and good morning, everyone. Michael Kaufmann - Chief Executive Officer With that, I'll now turn the call over to Mike. During the Q&A portion of today's call, we please ask that you try and limit yourself to one question, so that we can try and give everyone an opportunity. GAAP to non-GAAP reconciliations for all relevant periods can be found in the schedules attached to our press release. Please note that during our discussion today, our comments will be on a non-GAAP basis, unless they are specifically called out as GAAP.

#Customer order manager salary cardinal healt full

Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a full description of these risks and uncertainties. The matters addressed in the statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected or implied. Joining me today are Mike Kaufmann, Chief Executive Officer and Jason Hollar, Chief Financial Officer.ĭuring the call, we will be making forward-looking statements. You can find today's press release and presentation on the IR section of our website at ir. Today, we will discuss Cardinal Health's first quarter fiscal 2022 results.